Dolphin gel 3% and 5 %

Composition:

Each 100 gm contains:

Diclofenac sodium 3 gm or 5 gm
The base is an aqueous alcoholic gel without any fatty substances.

Properties:

Dolphin gel is anti-inflammatory and analgesic preparation for external application.
It contains 3% or 5% diclofenac sodium which is the active substance, in a non fatty base that is well tolerated by the skin.
The gel can be rubbed easily to the skin and due to its aqueous base ; it has a cooling and soothing effect.
When Dolphin gel is applied locally, diclofenac penetrates the skin, accumulates in the underlying tissues where it combats the acute and chronic inflammatory reactions.
By this effect Dolphin gel has a clinical response shown by pain relief, a marked decrease in inflammatory swelling through its analgesic and anti-inflammatory properties.

Indications:

For the local treatment:

- Traumatically induced inflammations of the tendons, ligaments, muscles, and joints (e.g. due to sprains, strains and contusions).
- Localized forms of non-articular soft tissue rheumatism (**tenosynovitis**, bursitis, tendonitis and shoulder-hand syndrome).
- Localized forms of rheumatic disease (e.g. osteoarthritis of peripheral joints and of the vertebral column and periarthropathy).

Dosage :

Depending on the size of the area to be treated, Dolphin gel should be applied to the skin 3-4 times daily and rubbed gently.

Dolphin gel should only be applied to intact areas of the skin only.
Wounds and open injuries, eyes and mucous membranes should not come into contact with this preparation.

Contraindications:

The preparation should not be used where there is hypersensitivity to diclofenac or the gel base, to acetyl salicylic acid or the other non-steroidal anti-inflammatory agents.
Dolphin gel should not be used under occlusive, airtight dressings, and is not to be taken by mouth.

Precautions & Warning

Elevation of one or more liver tests may occur during therapy with diclofenac. Diclofenac gel should be discontinued immediately if abnormal liver tests persist or worsen. In postmarketing reports, cases of drug-induced hepatotxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac.postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulfillment hepatitis with and without jaundice, and liver failure. some of these reported cases resulted in fatalities or liver transplantation. Physicians should measure transaminases periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms.

Cardiovascular Risk :

NSAIDS may cause an increased risk of serious cardivascular thrombotic events, myocardial infarction, and stroke, which can be fatal,
This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk · NSAIDS is contraindicated for the treatment of peri-operative pain in the setting of coronary .artery bypass graft (CABG) surgery.

Gastrointrstinal Risk :

NSAIDS may caus an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration,and perforation of the stomach or intestines, which can be fatal. These events can occur can at any time during use and with out warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

Side effects:

Dolphin gel is generally well tolerated. There may be occasional reports of itching, reddening of the skin, or skin rash of the treated area. The incidence of systemic effects cannot be excluded in case of longterm application on large areas of the skin.

Packing : Tube containing 30 gm .

Storage : Store at room temperature.

To be used under medical supervision
Keep out of reach of children

Produced by
DELTA PHARMA S.A.E
Tenth of Ramadan City , A.R.E.